Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial-Reference-Cited by-同舟云学术

Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial

Published:2016-05 Issue: Volume:59 Page:142-151
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hannan Raquibul,Tumati Vasu^ORCID,Xie Xian-Jin,Cho L. Chinsoo^ORCID,Kavanagh Brian D.,Brindle Jeffrey,Raben David,Nanda Akash,Cooley Susan,Kim D.W. Nathan,Pistenmaa David,Lotan Yair,Timmerman Robert

Funder

US Department of Defense

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962–1984);Lloyd-Davies;Urology,1990

2. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer;King;Int J Radiat Oncol Biol Phys,2012

3. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results;Madsen;Int J Radiat Oncol Biol Phys,2007

4. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy;Duchesne;Int J Radiat Oncol Biol Phys,1999

5. What hypofractionated protocols should be tested for prostate cancer?;Fowler;Int J Radiat Oncol Biol Phys,2003

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a Quality Metric Score to Assess the Placement of Hydrogel Rectal Spacer in Patients Treated With Prostate Stereotactic Radiation Therapy;Advances in Radiation Oncology;2024-03

2. To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer;International Journal of Radiation Oncology*Biology*Physics;2023-12

3. Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial;Frontiers in Oncology;2023-11-07

4. An optimal method of hydrogel spacer insertion for stereotactic body radiation therapy of prostate cancer;Japanese Journal of Radiology;2023-11-07

5. Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer;European Urology Oncology;2023-11